MCL1 and cervical carcinoma: Our data demonstrate that inhibition of USP13 with Spautin-1 reduces Mcl-1 expression and sensitises cervical cancer cells to the BH3 mimetic ABT-263, offering a potential therapeutic strategy for cervical cancer.